Warning: file_put_contents(/opt/frankenphp/design.onmedianet.com/storage/proxy/cache/10674a89e53455ac7a9283a3c841a575.html): Failed to open stream: No space left on device in /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php on line 36

Warning: http_response_code(): Cannot set response code - headers already sent (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 17

Warning: Cannot modify header information - headers already sent by (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 20
Lys-MDMA - Wikipedia Jump to content

Lys-MDMA

Add links
From Wikipedia, the free encyclopedia
Lys-MDMA
Clinical data
Other namesLysine-MDMA; N-(L-Lysinamidyl)-3,4-methylenedioxymethamphetamine; N-(L-Lysinamidyl)-MDMA; lysMDMA
Drug classSerotonin–norepinephrine–dopamine releasing agent; Entactogen; Empathogen
Identifiers
  • (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]-N-methylhexanamide
CAS Number
PubChem CID
Chemical and physical data
FormulaC17H27N3O3
Molar mass321.421 g·mol−1
3D model (JSmol)
  • CC(CC1=CC2=C(C=C1)OCO2)N(C)C(=O)[C@H](CCCCN)N
  • InChI=1S/C17H27N3O3/c1-12(20(2)17(21)14(19)5-3-4-8-18)9-13-6-7-15-16(10-13)23-11-22-15/h6-7,10,12,14H,3-5,8-9,11,18-19H2,1-2H3/t12?,14-/m0/s1
  • Key:MJBFXZNNDCEDME-PYMCNQPYSA-N

Lys-MDMA, or lysine-MDMA, also known as N-(L-lysinamidyl)-MDMA, is a putative prodrug of MDMA which is being investigated for possible use as a pharmaceutical drug in the treatment of psychiatric disorders.[1][2][3][4][5] Structurally, lys-MDMA is to MDMA as lisdexamfetamine is to dextroamphetamine[4][3] As of August 2024, a phase 1 clinical trial comparing MDMA, MDA, lys-MDMA, and lys-MDA has been conducted and completed.[1][2][5] Lys-MDMA is being developed by MindMed.[2][5]

A 2025 clinical study unexpectedly found that lys-MDMA does not convert into MDMA in humans and is completely inactive.[6] This is in contrast to lisdexamfetamine and lys-MDA, where are converted into dextroamphetamine and MDA, respectively.[6] The lack of conversion was attributed to steric hindrance caused by the N-methyl group of lys-MDMA.[6]

See also

[edit]

References

[edit]
  1. ^ a b Elliott SP, Holdbrook T, Brandt SD (May 2020). "Prodrugs of New Psychoactive Substances (NPS): A New Challenge" (PDF). Journal of Forensic Sciences. 65 (3): 913–920. doi:10.1111/1556-4029.14268. PMID 31943218. Lisdexamfetamine (N-(1-phenylpropan-2-yl)lysinamide) (Fig. 1A) can be prescribed in the treatment of attention deficit hyperactivity disorder (ADHD) in children and binge eating disorder in adults and consists of dextroamphetamine (d-amphetamine) derivatized with the amino acid L-lysine (11,12). While lisdexamphetamine itself is pharmacologically inactive, in vivo peptidase enzymes associated with red blood cells hydrolyze the amide bond, thereby allowing pharmacological effects being exerted through d-amphetamine (13). The delayed absorption and metabolic profile for formation of the active drug reduces lisdexamfetamine's abuse liability and increases its safety profile (11,12). However, use of lisdexamfetamine has been mentioned in some Internet user forums as well as lysineMDMA (5,14,15).
  2. ^ a b c Clinical trial number NCT04847206 for "Effects of MDMA-like Substances in Healthy Subjects (MDMA-like)" at ClinicalTrials.gov
  3. ^ a b US 11896670, Trachsel D, Liechti ME, Lustenberger F, "Synthesis routes to access MDMA prodrugs by using controlled and non-controlled intermediates", issued 13 February 2024, assigned to Mind Medicine Inc. 
  4. ^ a b "(2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]-N-methylhexanamide". PubChem. U.S. National Library of Medicine. Retrieved 13 November 2024.
  5. ^ a b c Mind Medicine (MindMed) (20 September 2022). "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". PR Newswire. Retrieved 13 November 2024.
  6. ^ a b c Straumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, Eckert A, Luethi D, Rudin D, Liechti ME (September 2025). "Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants". Neuropsychopharmacology. doi:10.1038/s41386-025-02248-3. PMID 40999236.
[edit]


Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lys-MDMA&oldid=1314003016"